Methylphenidate in children with hyperactivity: review and cost-utility analysis.
about
Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD)Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescentsSocial skills training for Attention Deficit Hyperactivity Disorder (ADHD) in children aged 5 to 18 yearsSocial skills training for children with attention deficit hyperactivity disorder (ADHD)A review of the economic burden of ADHDFrom Clinical Application to Cognitive Enhancement: The Example of MethylphenidateThe effect of methylphenidate on neurofibromatosis type 1: a randomised, double-blind, placebo-controlled, crossover trial.Randomised social-skills training and parental training plus standard treatment versus standard treatment of children with attention deficit hyperactivity disorder - the SOSTRA trial protocol.Child mental health in Latin America: present and future epidemiologic research.Is adjunctive pharmacotherapy in attention-deficit/hyperactivity disorder cost-effective in Canada: a cost-effectiveness assessment of guanfacine extended-release as an adjunctive therapy to a long-acting stimulant for the treatment of ADHD.Treatment for ADHD: is more complex treatment cost-effective for more complex cases?Meditation or Medication? Mindfulness training versus medication in the treatment of childhood ADHD: a randomized controlled trial.Annotation: Economic evaluations of child and adolescent mental health interventions: a systematic review.Cost effectiveness of guanfacine extended release as an adjunctive therapy to a stimulant compared with stimulant monotherapy for the treatment of attention-deficit hyperactivity disorder in children and adolescentsOmega-3 fatty acid treatment of children with attention-deficit hyperactivity disorder: A randomized, double-blind, placebo-controlled studyCosts associated with attention deficit hyperactivity disorder: overview and future projections.Cost effectiveness of methylphenidate versus AMP/DEX mixed salts for the first-line treatment of ADHD.Cost effectiveness of pharmacotherapies for attention-deficit hyperactivity disorder: a systematic literature review.The estimation of utility weights in cost-utility analysis for mental disorders: a systematic review.ADHD in children: a path to free medicines.Individual change in methylphenidate use in a national sample of children aged 2 to 11 years.Cognitive and Behavioral Disorders in Children with Neurofibromatosis Type 1.Agreement between parent and child report of quality of life in children with attention-deficit/hyperactivity disorder.
P2860
Q22061981-1FEF6221-3E1F-43E3-B2C7-209A4F406F16Q24198192-8C828FEC-EEB4-4EE7-8769-3F0320B4D8BDQ24234231-53239005-1C69-48F4-9F48-547F368555B7Q24239933-F898FC80-2B31-429D-A444-B9720682FC57Q24815063-ACEA5D0C-A220-4EB0-B135-2B53BE555319Q28073785-C0410A2D-039E-4908-B11F-45F68AB7966AQ34233624-F28213AF-1549-44A8-831F-17D61E683409Q34573882-0856C1C7-5BAC-477C-9246-B3C4D0B6A7E2Q35747754-5ACAD193-4F64-4932-91B0-080022280BFBQ35896019-D9B7178A-15F1-4BFC-9C5B-FB6D8802A8D8Q35954908-7BE8D179-046C-46B8-96E1-2FB49AB0D1D6Q36086314-957CF269-6D0B-472F-919B-2CC0265DF288Q36234219-3F834D9F-D666-4821-8749-9A784AD1A64EQ36623089-D3D385A5-40B5-4674-B601-AB7AA6EFA443Q37141442-2BF8F94F-37BA-4444-A473-BD3B59A2AEE0Q37609230-EA23AC01-4C24-4BAC-ADAD-3E842F3F5426Q37609357-1F8B10CE-16CB-4D08-83CE-607B842D4DB5Q38019961-5A16ED2E-6DC2-485B-8F0D-B01A31B11284Q38167693-E01414A9-DD05-41A3-B610-09041A4687A6Q41448511-65C361DD-9BBF-47BC-810B-FBC076475B0AQ46438027-29AAEE29-C8D2-4D20-8FA5-FD3C285378B4Q47150280-257D80F0-CD5E-4AE4-AEF7-DFE53437B9BEQ51915852-D19D8534-6E03-4AF3-B944-B78224F37EA7
P2860
Methylphenidate in children with hyperactivity: review and cost-utility analysis.
description
2001 nî lūn-bûn
@nan
2001 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի մարտին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Methylphenidate in children with hyperactivity: review and cost-utility analysis.
@ast
Methylphenidate in children with hyperactivity: review and cost-utility analysis.
@en
Methylphenidate in children with hyperactivity: review and cost-utility analysis.
@nl
type
label
Methylphenidate in children with hyperactivity: review and cost-utility analysis.
@ast
Methylphenidate in children with hyperactivity: review and cost-utility analysis.
@en
Methylphenidate in children with hyperactivity: review and cost-utility analysis.
@nl
prefLabel
Methylphenidate in children with hyperactivity: review and cost-utility analysis.
@ast
Methylphenidate in children with hyperactivity: review and cost-utility analysis.
@en
Methylphenidate in children with hyperactivity: review and cost-utility analysis.
@nl
P2860
P356
P1476
Methylphenidate in children with hyperactivity: review and cost-utility analysis.
@en
P2093
P2860
P356
10.1002/PDS.564
P577
2001-03-01T00:00:00Z